Eye care:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • Prescribing information can be found at the bottom of this page

      Retinal disease

      OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:

      teaser1

      Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy

      Find out more
      teaser2

      Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion  (CRVO)

      Content coming soon

      Job Number ALL-OZU-220048. Date of Preparation March 2023

      OZURDEX® PRESCRIBING INFORMATION
      AbbViePro Logo 2023
      AbbViePro Logo 2023
      Our therapy areas
      Immunology
      Oncology
      Neuroscience
      Virology
      Eye Care
      Additional info
      Privacy Notice
      Terms of Use
      Contact Us

      Report Adverse Event (AE reporting requirements to be localized)

      This website is for Healthcare Professionals only


      Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.


      © 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.